Atovaquone Oral Suspension Recalled for Bacillus cereus Contamination
Camber Pharmaceuticals is recalling Atovaquone Oral Suspension due to contamination by Bacillus cereus bacteria. The contamination was discovered during testing of repackaged medication.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: This FDA Class I recall requires a minimum severity of 4 per regulatory guidelines. The actual detection of Bacillus cereus contamination in a prescription medication justifies the Severe classification despite no reported illnesses.
Plain-English summary
Camber Pharmaceuticals Inc. is recalling Atovaquone Oral Suspension USP (750 mg/5 mL) because testing identified Bacillus cereus contamination in repackaged product. The contaminated lot (E220182, expiring December 31, 2023) includes 1,568 bottles. This is an FDA Class I recall, the agency's most serious classification.
The recalled medication was distributed nationwide in the United States. Patients taking this medication should contact their healthcare provider immediately. Do not continue use of the affected product without consulting a healthcare provider about alternatives.
The recalled product
- Product
- ATOVAQUONE (ATOVAQUONE)
- Brand
- ATOVAQUONE
- Manufacturer
- Camber Pharmaceuticals Inc.
- Category
- Drug — Antimalarial
- Hazard
- microbial-contamination
- bacillus-cereus
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot# E220182
- Exp. 12/31/2023
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · ATOVAQUONE
- SevereAtovaquone Oral Suspension Recalled for Cohnella Bacteria Contamination
FDA (Drugs) · 2024-10-23
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27